EGFR and neoplasm: Camorani et al. reported that an anti-EGFR directed aptamer, but not erlotinib or cetuximab, prevented VM by MDA-MB-231 through disruption of the integrin αvβ3 interaction with EGFR and inhibited tumor growth [63].